Exelixis
EXEL
#1673
Rank
ยฃ7.87 B
Marketcap
ยฃ27.59
Share price
-0.60%
Change (1 day)
61.29%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): ยฃ0.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is ยฃ0.22. In 2022 the company made an earnings per share (EPS) of ยฃ0.45 a decrease over its 2021 EPS that were of ยฃ0.59.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)ยฃ0.22-50.51%
2022ยฃ0.45-22.97%
2021ยฃ0.59100%
2020ยฃ0.29-65.09%
2019ยฃ0.84-53.91%
2018ยฃ1.82333.96%
2017ยฃ0.42-260.61%
2016-ยฃ0.26-58.75%
2015-ยฃ0.63-42.45%
2014-ยฃ1.105.3%
2013-ยฃ1.0543.48%
2012-ยฃ0.73-264.29%
2011ยฃ0.44-165.88%
2010-ยฃ0.67-32.54%
2009-ยฃ1.00-17.65%
2008-ยฃ1.2175.86%
2007-ยฃ0.69-25.64%
2006-ยฃ0.938.33%
2005-ยฃ0.86-42.86%
2004-ยฃ1.5030.34%
2003-ยฃ1.15-5.23%
2002-ยฃ1.21-0.65%
2001-ยฃ1.22-51.88%
2000-ยฃ2.53

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
ยฃ2.77 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ2.52 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ1.44 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.14 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ11.20 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ11.15 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.47 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ7.92-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.67-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA